A New Era of Immunotherapy: How Might This Impact Breast Cancer Management


Date
Wednesday, October 5, 2016 - Thursday, October 5, 2017 12:00 AM   Online, IN

Objectives
  1. Identify the steps of the cancer-immunity cycle and the potential for intervention at each step
  2. Be familiar with the mechanism of action and toxicities of the checkpoint inhibitors
  3. Describe the interactions of the immune system with both standard and experimental treatments for breast cancer, both stimulatory and suppressive

Accreditation
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Indiana University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor.  All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. 

The planning committee and those in a position to control the content of this activity have disclosed no relevant financial relationships.